To further establish the phenotype of the tumour-associated macrophages (TAMs) that express PDLIM2, we analyzed the percentage of PDLIM2-positive or -negative tumours that expressed low or medium/high levels of CD163. This evidence concerns the gene CD163 and neoplasm.